Bristol Myers Squibb Co. closed 3.76% short of its 52-week high of $61.10, which the company achieved on January 27th.

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 13.7%. Its stock price has climbed to $58.28, ...

Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) saw some unusual options trading on Tuesday. Traders acquired 46,473 call options on the company. This represents an increase of approximately 61% ...

In a regulatory filing on Friday night, Bristol Myers (BMY) disclosed that its CEO Christopher Boerner bought 2K shares of common stock on ...

A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...

Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...

Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...

Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult ...

Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics ...

Shares of Bristol Myers Squibb Co. BMY slid 1.43% to $57.38 Wednesday, on what proved to be an all-around mixed trading ...